Background and aims Besides LDL-cholesterol, local vascular inflammation plays a key role
in atherogenesis. Efficient therapies to treat the inflammatory component of the disease have
not been established. The discovery of specialized inflammation-resolving mediators, such
as resolvins may provide new opportunities for treatment. This study examines whether the
ω-3 fatty acid eicosapentaenoic acid-derived resolvin E1 (RvE1), can reduce
atherosclerosis, when administered alone or in combination with a cholesterol-lowering …